A pivotal Phase III study evaluating the use of dupilumab in eosinophilic esophagitis (EoE).
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- 19 Dec 2017 New trial record
- 13 Dec 2017 According to a Regeneron pharmaceutical media release, this study is planned to initiate in 2018.